key: cord-0770878-1zn3n1sn
authors: Tinio, Patricia Anne; Melendres, Jacqueline Michelle; Chavez, Czarina P.; Agon, Maicka Keirsten; Merilleno, Arbie Sofia; Balagat, Rogelio; Tumalad, Lily Lyralin; Amado, Alma Gay Concepcion; Rivera, Francisco
title: Clinical profile and response to treatment of patients with psoriasis seen via teledermatology during the COVID-19 pandemic in the Philippines
date: 2022-02-10
journal: JAAD Int
DOI: 10.1016/j.jdin.2022.02.001
sha: 2a0d1203ebf4c3393180dcf2dcb9180e5043bcb9
doc_id: 770878
cord_uid: 1zn3n1sn

nan

To the Editor: Psoriasis is a chronic disease that requires long-term follow-up. The COVID-19 pandemic has prompted us to increase the use of teledermatology (TD) to care for our patients with psoriasis. We conducted a descriptive cross-sectional study of our patients with psoriasis seen via TD during the pandemic, describing their demographic and clinical profile and evaluating their response to treatment.

We reviewed 424 charts of patients with psoriasis seen via TD who had new-onset psoriasis flareup and who had a follow-up at 1 month. The study duration was from October 2020 to April 2021. Table I shows the demographic and clinical profile of the cohort. Treatment response was evaluated by comparing the psoriasis area severity index (PASI) and dermatology life quality index (DLQI) at the time of new-onset flareup and at follow-up at 1 month (Table II) . Mean PASI and DLQI decreased from the baseline to follow-up. PASI and DLQI reduction was the highest for severe disease, 26% and 18%, respectively. Moderate psoriasis had a 20% and 13% reduction, respectively, whereas mild disease had a 19% and 11% reduction, respectively, in PASI and DLQI.

Our study provides real-world data on the use of TD to care for patients with psoriasis during the pandemic. It is noteworthy that our patients were younger than those of 2 registry-based studies, the study by Ng et al 1 before the pandemic and the study by Mahil et al 2 during the pandemic, which had a mean age of patient of 44 years (SD, 16 years) and 47.2 years (SD, 15.1 years), respectively. It is possible that younger patients are more adept at using technology than older patients and may explain the greater number of patients aged \40 years in our study. We recommend a study on TD utilization patterns and feedback to help older patients keep abreast of technology.

Forty-six percent of our patients reported mental stress as a trigger of the disease flareup. This may be attributed to the effects of the pandemic, which has restricted mobility, caused the loss of income, and has led to stress, anxiety, and depression. 3 We encourage psychosocial support for these patients.

The reduction in PASI and DLQI in our patients across all severity groups suggests that TD is a useful alternative in caring for patients with psoriasis, especially in this pandemic. In our institution, we use hybrid TD because most of our patients do not have a reliable internet connection, which precludes good-quality video conferencing. Hybrid TD allows us to better assess the condition through photographs sent via the Facebook messenger (store-and-forward TD) combined with a telephonic call (real-time interactive TD) to review patients' clinical history and explain management. We use the Facebook messenger because it is accessible to most patients, including those from resource-poor regions. Similarly, Angeles et al 4 reported that most dermatologists in the Philippines use hybrid TD, with the Facebook messenger as the second most commonly used platform.

Limitations of our study include the lack of a control group and long-term follow-up. To validate our findings, we recommend including a cohort of patients with psoriasis seen in-office as a control group and including long-term follow-up assessments in future studies.

Dr Tinio has received honoraria as a member of the advisory board and speaker from Novartis, Janssen/J&J, and Zuellig Lilly. Dr Chavez has received fees as a speaker from LeoPharma and Glenmark and a research grant paid to her institution as principal investigator from Glenmark. Dr Balagat has received fees as a speaker from Novartis. Dr Tumalad has received honoraria as a speaker from Novartis, LeoPharma, and J&J and research funds as principal investigator from Novartis. Drs Melendres, Agon, Merilleno, Amado, and Rivera have no conflicts of interest to declare.

Demographic and clinical profiles of adult Filipino patients with psoriasis in Davao City: a cross sectional study

Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study

Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: a web-based survey

Impact of the COVID-19 pandemic on dermatology practice in the Philippines: a cross-sectional study